Copyright
©The Author(s) 2015.
World J Gastrointest Pharmacol Ther. Nov 6, 2015; 6(4): 213-222
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.213
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.213
Figure 7 Histopathology analysis of colon tissues after treatment with dolcanatide.
Representative histopathological images of the large bowel from the DSS-induced colitis study are depicted. Criteria for scoring colitis severity were as described under Materials and Methods. A: Untreated naïve mice, histopathology score = 0; B: DSS + vehicle treated, histopathology score = 3; C: DSS + dolcanatide (0.05 mg/kg), histopathology score = 2; D: DSS + 5-ASA (100 mg/kg), histopathology score = 2. Arrows in panel B indicate morphological deterioration in crypts and villi of GI mucosa. DSS: Dextran sulfate sodium; 5-ASA: 5-amino salicylic acid; GI: Gastrointestinal.
- Citation: Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther 2015; 6(4): 213-222
- URL: https://www.wjgnet.com/2150-5349/full/v6/i4/213.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v6.i4.213